BS
Therapeutic Areas
Karyopharm Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Selinexor (XPOVIO®) | Multiple Myeloma | Approved/Commercial |
| Selinexor | Acute Myeloid Leukemia (AML) | Clinical Trials |
| Eltanexor (KPT-8602) | Myelodysplastic Syndromes (MDS) | Phase 1/2 |
| Verdinexor (KPT-335) | Solid Tumors & Lymphoma | Phase 1 |
Leadership Team at Karyopharm Therapeutics
RP
Richard Paulson
President and Chief Executive Officer
LM
Lori Macomber
Executive Vice President, Chief Financial Officer and Treasurer
RR
Reshma Rangwala
Chief Medical Officer & Head of Research
SP
Stuart Poulton
Chief Development Officer
MM
Mike Mano
Executive Vice President, Chief Legal Officer and Secretary
SC
Sohanya Cheng
Chief Commercial Officer and Head of Business Development
LD
Lisa DiPaolo
Chief Human Resources Officer
AS
Amama Sadiq
Senior Vice President, Global Medical and Scientific Affairs
BA
Brian Austad
Senior Vice President, Pharmaceutical Sciences
JA
James Accumanno
Chief Compliance Officer